Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

IntroductionMatching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. Unlike traditional single marker tests, comprehensive genomic profiling (CG...

Full description

Saved in:
Bibliographic Details
Main Authors: Zachary D. Wallen, Mary K. Nesline, Marni Tierno, Alison Roos, Erica Schnettler, Hatim Husain, Pratheesh Sathyan, Brian Caveney, Marcia Eisenberg, Eric A. Severson, Shakti H. Ramkissoon
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
genomic profiling
immune checkpoint inhibitors
TMB
PD-L1
clinical utility
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1473327/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1473327/full

Similar Items